Department of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Int J Antimicrob Agents. 2012 Apr;39(4):332-7. doi: 10.1016/j.ijantimicag.2011.12.008. Epub 2012 Feb 12.
Vancomycin is frequently administered to critically ill patients by continuous infusion in order to optimise drug efficacy; however, there are few data available on the efficacy of this strategy in septic patients. In this retrospective analysis, 261 patients treated with continuous infusion of vancomycin in the Department of Intensive Care at Hôpital Erasme (Brussels, Belgium) were evaluated. Creatinine clearance (CL(Cr)) was calculated from 24-h urine collection and normalised to body surface area. During the study period, 139 patients (53%) had insufficient vancomycin concentrations (<20 μg/mL) on Day 1 and 87 patients (33%) on Day 2. Patients who had insufficient drug concentrations on Day 1 of therapy were more likely to be men, to have a higher CL(Cr) and to have received lower loading and daily vancomycin doses than other patients, who received greater vasopressor support and had higher Sepsis-related Organ Failure Assessment scores. In multivariate regression analysis, high CL(Cr) and male sex independently predicted the presence of insufficient vancomycin concentrations on Days 1 and 2 of therapy. Receiver operating characteristic curve analysis for CL(Cr) showed an area under the concentration-time curve of 0.75 (95% confidence interval 0.69-0.81) to predict insufficient drug concentrations on Day 1 of therapy. A CL(Cr)>120 mL/min/1.73 m(2) had a sensitivity of 26%, a specificity of 94% and an 84% positive predictive value of 84% for vancomycin concentrations <20 μg/mL. In conclusion, approximately one-half of the septic Intensive Care Unit patients treated with continuous infusion of vancomycin at currently recommended doses had insufficient drug concentrations in the early phase of therapy. A high CL(Cr) was the variable most strongly associated with insufficient drug concentrations.
万古霉素常通过连续输注用于重症患者,以优化药物疗效;然而,关于该策略在脓毒症患者中的疗效的数据很少。在这项回顾性分析中,评估了在比利时布鲁塞尔 Erasme 医院重症监护病房接受万古霉素连续输注治疗的 261 名患者。通过 24 小时尿液采集计算肌酐清除率(CL(Cr)),并按体表面积进行标准化。在研究期间,第 1 天有 139 名(53%)患者的万古霉素浓度不足(<20μg/mL),第 2 天有 87 名(33%)患者的万古霉素浓度不足。在治疗的第 1 天药物浓度不足的患者更可能是男性,CL(Cr)更高,接受的负荷剂量和日剂量更低,而接受更大血管加压支持和更高的脓毒症相关器官衰竭评估评分的患者则更高。在多变量回归分析中,高 CL(Cr)和男性独立预测了治疗第 1 天和第 2 天万古霉素浓度不足的存在。CL(Cr)的受试者工作特征曲线分析显示,浓度-时间曲线下面积为 0.75(95%置信区间 0.69-0.81),以预测治疗第 1 天药物浓度不足。CL(Cr)>120 mL/min/1.73 m(2)对<20μg/mL 万古霉素浓度的敏感性为 26%,特异性为 94%,阳性预测值为 84%。总之,目前推荐剂量下接受连续输注万古霉素治疗的大约一半脓毒症重症监护病房患者在治疗早期药物浓度不足。高 CL(Cr)是与药物浓度不足最相关的变量。